These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8587010)

  • 41. Hemodynamic effects of the Fab fragment of digoxin antibody (digibind) in corticotropin (ACTH)-induced hypertension.
    Li M; Wen C; Whitworth JA
    Am J Hypertens; 1997 Mar; 10(3):332-6. PubMed ID: 9056691
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the pharmacokinetics and in vivo bioaffinity of DigiTAb versus Digibind.
    Ward SB; Sjostrom L; Ujhelyi MR
    Ther Drug Monit; 2000 Oct; 22(5):599-607. PubMed ID: 11034267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma digoxin: assay anomalies in Fab-treated patients.
    Gibb I; Adams PC; Parnham AJ; Jennings K
    Br J Clin Pharmacol; 1983 Oct; 16(4):445-7. PubMed ID: 6626440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparable effects of DIGIBIND and DigiFab in thirteen digoxin immunoassays.
    McMillin GA; Owen WE; Lambert TL; De BK; Frank EL; Bach PR; Annesley TM; Roberts WL
    Clin Chem; 2002 Sep; 48(9):1580-4. PubMed ID: 12194938
    [No Abstract]   [Full Text] [Related]  

  • 45. Predictive performance study of two digoxin assays in subjects with various degrees of renal function.
    Spinler SA; Al-Jazairi AS; Cheng JW; Kapoor S; Kobrin S; Shaw L
    Ther Drug Monit; 2000 Dec; 22(6):729-36. PubMed ID: 11128242
    [TBL] [Abstract][Full Text] [Related]  

  • 46. False-positive serum digoxin concentrations determined by three digoxin assays in patients with liver disease.
    Frisolone J; Sylvia LM; Gelwan J; Pal S; Pellechia C
    Clin Pharm; 1988 Jun; 7(6):444-9. PubMed ID: 3402179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments.
    George S; Braithwaite RA; Hughes EA
    Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():380-2. PubMed ID: 7979107
    [No Abstract]   [Full Text] [Related]  

  • 48. Neutralization of free digoxin-like immunoreactive components of oriental medicines Dan Shen and Lu-Shen-Wan by the Fab fragment of antidigoxin antibody (Digibind).
    Dasgupta A; Szelei-Stevens KA
    Am J Clin Pathol; 2004 Feb; 121(2):276-81. PubMed ID: 14983943
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.
    Ujhelyi MR; Robert S
    Clin Pharmacokinet; 1995 Jun; 28(6):483-93. PubMed ID: 7656506
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recurrence of digoxin toxicity following treatment with digoxin immune fab in a patient with renal impairment.
    Hazara AM
    QJM; 2014 Feb; 107(2):143-4. PubMed ID: 24023070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analytical performance of a monoclonal digoxin assay with increased specificity on the ACS:180.
    Miller JJ; Straub RW; Valdes R
    Ther Drug Monit; 1996 Feb; 18(1):65-72. PubMed ID: 8848824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Digoxin and digoxin derivative induced arrhythmias: in vitro binding and in vivo abolition of arrhythmias by digoxin immune Fab (DIGIBAND).
    Cambridge D; Morgan CR; Allen G
    Cardiovasc Res; 1992 Sep; 26(9):906-11. PubMed ID: 1451168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage.
    Nicholls DP; Murtagh JG; Holt DW
    Br Heart J; 1985 Apr; 53(4):462-4. PubMed ID: 3986060
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Free and total serum digoxin concentrations in a renal failure patient after treatment with digoxin immune Fab.
    Clifton GD; McIntyre WJ; Zannikos PN; Harrison MR; Chandler MH
    Clin Pharm; 1989 Jun; 8(6):441-5. PubMed ID: 2743737
    [No Abstract]   [Full Text] [Related]  

  • 55. Digoxin immune Fab therapy for digoxin toxicity.
    Phillips SD
    Ann Intern Med; 1994 Feb; 120(3):247. PubMed ID: 8273992
    [No Abstract]   [Full Text] [Related]  

  • 56. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies.
    Smith TW; Haber E; Yeatman L; Butler VP
    N Engl J Med; 1976 Apr; 294(15):797-800. PubMed ID: 943040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure.
    Lapostolle F; Borron SW; Verdier C; Arnaud F; Couvreur J; Mégarbane B; Baud F; Adnet F
    Intensive Care Med; 2008 Aug; 34(8):1448-53. PubMed ID: 18389220
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin, and cinobufotalin by digibind: monitoring the effect by measuring free digitoxin concentrations.
    Dasgupta A; Emerson L
    Life Sci; 1998; 63(9):781-8. PubMed ID: 9740315
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of four digoxin immunoassays with respect to interference from digoxin-like immunoreactive factors.
    Datta P; Hinz V; Klee G
    Clin Biochem; 1996 Dec; 29(6):541-7. PubMed ID: 8939401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Competitive solid-phase enzyme immunoassay for measuring digoxin in serum.
    Hinds JA; Pincombe CF; Morris H; Duffy P
    Clin Chem; 1986 Jan; 32(1 Pt 1):16-21. PubMed ID: 3510090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.